The Spanish company announces the granting of a patent for cancer therapy in the oceanic country.
Spanish biopharmaceutical company Oryzon Genomics has announced that it continues to expand its patent portfolio for iadademstat and vafidemstat, its clinical-stage LSD1 inhibitors for oncology and central nervous system disorders.
Specifically, the Australian Patent Office has issued a Grant Decision for Oryzon's patent application entitled ‘Combinations of iadademstat for cancer therapy’. The approved claims cover combinations of iadademstat with PD1 or PD-L1 inhibitors for the treatment of cancer, including small cell lung cancer (SCLC). A Grant Decision is an official communication from a national patent office indicating that a patent application has met all the requirements for grant as a patent. Once formally granted, this Australian patent will remain in force until at least 2040, not including potential patent extensions. A corresponding patent has also been granted in Russia, and applications are pending in Europe, the United States, Japan, China and other countries.
Iadademstat is currently being evaluated in combination with PD-L1 inhibitors (atezolizumab or durvalumab) in patients with first-line extensive CPCP in a Phase I/II clinical trial sponsored and conducted by the US National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Oryzon. (NCI) under a Cooperative Research and Development Agreement (CRADA) with Oryzon. More than 30 centres in the United States are participating in the trial, including leading institutions such as Memorial Sloan Kettering Cancer Centre, Johns Hopkins, City of Hope, Yale University and the University of Chicago, among others.
Neus Virgili, Director of Patents at Oryzon, points out that ‘these new grants (the one in Australia and another approved in Europe) strengthen Oryzon's global patent position by protecting key therapeutic indications under clinical development for iadademstat and vafidemstat, thus extending the commercial life of both compounds’.
Read the news on the Oryzon website
